spacer
home > ict > autumn 2017 > three-fold solution
PUBLICATIONS
International Clinical Trials

Three-Fold Solution

Astonishingly, the same four problems that delayed trial
start-ups 20 years ago are still doing so today; very little has
changed. Sponsors, CROs and investigator sites consistently
name redundant training and certification, budgeting
and contracting issues, vendor relations and scheduling
concerns as the top reasons that site activation can take
up to a year (1).

Certainly, these are not the only issues that cause stoppage.
Feasibility studies, regulatory matters and institutional
review board (IRB) approvals play their part, but the ‘big
four’ remain the same. However, stakeholders can embrace
a three-fold solution to speed up trial start dates, which
has the potential to slash site activation times to as little
as 30 days.

The ‘Big Four’

Before turning to the solution, having a clear
understanding of the problems preventing swift site
activation is important.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sean Stanton is Senior Vice President Global Operations at Bioclinica Research Network. He has dedicated the last 25 years of his career to creating successful, high-performing research sites and, to date, has led the start-up of 25 trial sites, six inpatient hospitals and 19 outpatient clinics. More than 5,000 trials have been conducted at these sites, leading to over 50 drug approvals, and, in these, he directed recruitment for the screening of 2,000 to 6,000 patients annually. A sought-after industry expert, Sean has brought innovative thinking to research in all aspects of site practice, from purchasing and resourcing to the use of benchmarking and metrics in business planning to guide trial growth.
spacer
Sean Stanton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the release of a published white paper detailing Domino’s study which analyzes potential leachability of ink from coding technologies used in pharmaceutical Serialization activities. The study was executed to ensure no migration into drug product contained within HDPE bottles with directly applied codes. Domino is an industry leader in coding and printing technologies operating in over 120 countries worldwide, and one of the key providers of coding technologies to PCI across its global supply network.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

ASPIRE: International EDGE Conference

28 February - 1 March 2018, The Vox Conference Centre, Birmingham

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement